Look for:

Our offer for

NOVO-NORDISK AS B


ISIN:
DK0060534915
WKN:
-

2023/02/08 18:20:39
Price
129.44 EUR
Difference -0.14% (-0.18)

General attributes

ISINDK0060534915
SymbolNOVO B
ExchangeBerlin
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)222,343 EUR
BenchmarkOMX COPENHAGEN 20

Market data

Bid (Bid size)129.98 EUR (150)
Ask (Ask size)130.52 EUR (150)
Open130.32 EUR
High132.10 EUR
Low129.44 EUR
Close (prev. day)129.62 EUR
VWAP-
Volume (pcs)1,007
Trading volume131,439.38
Number of trades4
Last size2

Futures and Options

Related Futures12
Related Options-

PDF Downloads

Company report: NOVO-NORDISK AS BPDF Download

Scale: ABS REL         Instrument
Interactive chart

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

Date Headline Download
2023/02/07 en Global Equity Ratings PDF Download
2023/01/30 en Global Equity Ratings PDF Download
2023/01/09 en Global Equity Ratings PDF Download
2022/12/19 en Global Equity Ratings PDF Download
2022/11/28 en Global Equity Ratings PDF Download


2023/02/08 18:20:39
Price
129.44 EUR
Difference -0.14% (-0.18)

General attributes

ISINDK0060534915
SymbolNOVO B
ExchangeBerlin
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)222,343 EUR
BenchmarkOMX COPENHAGEN 20

Market data

Bid (Bid size)129.98 EUR (150)
Ask (Ask size)130.52 EUR (150)
Open130.32 EUR
High132.10 EUR
Low129.44 EUR
Close (prev. day)129.62 EUR
VWAP-
Volume (pcs)1,007
Trading volume131,439.38
Number of trades4
Last size2

Performance and Risk

6m1Y3Y
Perf (%)+28.08%+48.87%+124.37%
Perf (abs.)+28.42+42.55+71.85
Beta1.071.101.07
Volatility25.5831.0730.16
Scale: ABS REL         Instrument
Interactive chart

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)126.63 EUR (2,128)
Ø price 30 days | Ø volume 30 days (pcs.)127.43 EUR (393)
Ø price 100 days | Ø volume 100 days (pcs.)116.55 EUR (145)
Ø price 250 days | Ø volume 250 days (pcs.)108.66 EUR (94)
YTD High | date131.12 EUR (2023/01/04)
YTD Low | date121.24 EUR (2023/02/03)
52 Weeks High | date131.12 EUR (2023/01/04)
52 Weeks Low | date82.60 EUR (2022/02/22)

All listings for NOVO-NORDISK AS B

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Xetra2023/02/0817:35130.00 EUR2.27353
Vienna Stock Exchange2023/02/0817:32130.40 EUR0.016
Tradegate2023/02/0820:19130.06 EUR2.74325
Stuttgart2023/02/0819:06130.14 EUR0.0614
SIX Swiss Exchange2023/01/2417:36135.00 CHF0.001
Nasdaq Copenhagen2023/02/0816:59970.80 DKK1,952.1717,503
Munich2023/02/0808:04130.38 EUR0.001
London Stock Exchange European Trade Reporting2023/02/0817:08970.3146 DKK4.2437
Hanover2023/02/0814:12131.68 EUR0.003
Hamburg2023/02/0814:18131.50 EUR0.024
Frankfurt2023/02/0819:14129.30 EUR0.1122
FINRA other OTC Issues2023/02/0818:49139.42 USD7.1117
Duesseldorf2023/02/0818:31129.42 EUR0.0010
Berlin2023/02/0818:20129.44 EUR0.134
BX Swiss2023/02/0818:00130.274 CHF0.032

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=31640&ID_TYPE_IMAGE_LOGO=2

Contact Details

NOVO NORDISK A/S
- -
Novo Allé 1 - 2880 Bagsværd
Telefon: 45-44-44-88-88
Fax: -
E-mail: -

PDF Downloads

Company report: NOVO-NORDISK AS BPDF Download

Company Profile

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Members of Management Board

Lars Fruergaard JørgensenChairman of Managing Board
Jane Buus LaursenMember of Executive Committee
Marcus SchindlerMember of Executive Committee
Martin LangeMember of Executive Committee
Peter Jens Lindholm KurtzhalsMember of Executive Committee
Stephen GoughMember of Executive Committee
Camilla SylvestMember of Executive Committee
Daniel BohsenMember of Executive Committee
Doug LangaMember of Executive Committee
Henrik Ehlers WulffMember of Executive Committee
Irina IvanischevaMember of Executive Committee
Jill PriselacMember of Executive Committee
John McDonaldMember of Executive Committee
Karsten Munk KnudsenMember of Executive Committee
Ludovic HelfgottMember of Executive Committee
Maziar Mike DoustdarMember of Executive Committee
Monique CarterMember of Executive Committee
Robin EversMember of Executive Committee
Sergey ManelisMember of Executive Committee

Board of directors

Helge LundChairman of Supervisory Board
Martin MacKayMember of Supervisory Board
Sylvie GrégoireMember of Supervisory Board
Andreas FibigMember of Supervisory Board
Elisabeth ChristensenMember of Supervisory Board
Henrik PoulsenMember of Supervisory Board
Jeppe Fonager ChristiansenMember of Supervisory Board
Kasim KutayMember of Supervisory Board
Laurence DebrouxMember of Supervisory Board
Liselotte HyveledMember of Supervisory Board
Mette Bøjer JensenMember of Supervisory Board
Thomas RantzauMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer